Sunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate De...
November 30 2017 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the
appointment of William Quinn as Chief Financial Officer and Senior
Vice President, Finance and Corporate Development. Willie brings
deep and relevant healthcare industry experience to Sunesis, most
recently serving as CEO and Co-Founder of the private cancer
immunotherapy company Bullet Biotechnology. Prior to Bullet Bio, he
led Corporate Development and Strategy at Jazz Pharmaceuticals.
“Willie is a tremendous addition to the Sunesis
team with a track record of achievement in both finance and
corporate development,” said Daniel Swisher, Chief Executive
Officer of Sunesis. “We are ecstatic to have him join us now and
welcome his insights and expertise as we accelerate the development
of our non-covalent reversible BTK inhibitor SNS-062 and advance
the rest of our kinase inhibitor pipeline to key inflection
points.”
“I was drawn to this opportunity by the enormous
upside potential of Sunesis’ pipeline, and am thrilled to be
joining at this exciting time for the Company,” stated Mr. Quinn.
“SNS-062 has the potential to address significant unmet needs in
the treatment of hematological malignancies, and I look forward to
working with this high-performing leadership team to deliver on
Sunesis’ mission of developing new and better treatment options for
cancer patients.”
Prior to joining Sunesis, Mr. Quinn was
President and Chief Executive Officer of Bullet Biotechnology, a
company developing immunotherapies for cancer and autoimmune
diseases, which he founded in 2011. At Bullet Bio, Willie partnered
with multiple biopharma companies and universities, raised multiple
round of equity and convertible debt funding, and oversaw early
development of several products. From 2003 to 2011, Mr. Quinn held
various management positions at Jazz Pharmaceuticals, helping the
company grow from a four-person startup to a successful commercial
specialty pharmaceutical company. During his tenure at Jazz, Mr.
Quinn managed investor relations, partnering, mergers and
acquisitions, and strategic planning activities. He began his
career in the life science industry at Novation Biosciences. Willie
also has prior investing experience from his time as an Associate
Partner at Mobius Venture Capital.
Mr. Quinn obtained his MBA from the Stanford
Graduate School of Business and also earned an MA and BA from
Stanford University.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the future treatment of solid and hematologic
cancers. Sunesis has built an experienced cancer drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor, SNS-062, is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
SNS-062 is currently being evaluated in a Phase 1b/2, open-label,
sequential-group, dose-escalation and cohort-expansion study in
adults with chronic lymphocytic leukemia, Waldenstrom’s
macroglobulinemia, or mantle cell lymphoma who have progressed
after prior therapies. Beyond the development of SNS-062, the
Company has two other kinase inhibitor programs, including the
Takeda-partnered pan-RAF inhibitor TAK-580, which is in solid tumor
trials, and Sunesis’ proprietary preclinical PDK1 inhibitor
SNS-510, which has completed non-GLP toxicology studies and has
been designated a Development Candidate. PDK1 is a master
kinase that activates other kinases important to cell growth and
survival including members of the AKT, PKC, RSK and SGK
families.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to the continued
development of SNS-062, including the timing of Phase 1b/2 trial of
SNS-062 and the therapeutic potential of SNS-062, further
development and potential of its kinase inhibitor pipeline, and
planned development of SNS-510. Words such as “future,” “look
forward,” “potential,” “will” and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk related to the timing or
conduct of Sunesis' clinical trials, including SNS-062 Phase 1b/2
trial, the risk that Sunesis' clinical or preclinical studies for
SNS-062, SNS-510 or other product candidate may not demonstrate
safety or efficacy or lead to regulatory approval, the risk that
data to date and trends may not be predictive of future data or
results, risks related to the timing or conduct of Sunesis'
clinical trials, that Sunesis' development activities for SNS-062
or SNS-510 could be otherwise halted or significantly delayed for
various reasons, that Sunesis may not be able to receive regulatory
approval of SNS-062, or SNS-510 in the U.S. or Europe,
and risks related to Sunesis' ability to raise the capital that it
believes to be accessible and is required to fully finance the
development and commercialization of SNS-062, SNS-510 and other
product candidates. These and other risk factors are discussed
under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on
Form 10-Q for the quarter ended September 30, 2017 and
Sunesis' other filings with the Securities and Exchange
Commission. Sunesis expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein reflect any change in
Sunesis' expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor and Media
Inquiries: |
|
Maeve ConneightonArgot
Partners212-600-1902 |
Dan
SwisherSunesis Pharmaceuticals Inc.650-266-3715 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024